Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Above 200-Day Moving Average After Analyst Downgrade

Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report) shares passed above its 200-day moving average during trading on Tuesday after Weiss Ratings upgraded the stock from a sell (d-) rating to a sell (d) rating. The stock has a 200-day moving average of $2.27 and traded as high as $2.67. Aytu BioPharma shares last traded at $2.66, with a volume of 4,432,223 shares changing hands.

A number of other equities analysts have also recently issued reports on AYTU. Ascendiant Capital Markets increased their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Citigroup restated a “positive” rating on shares of Aytu BioPharma in a research note on Tuesday, September 22nd. Finally, Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Aytu BioPharma has a consensus rating of “Hold” and a consensus target price of $8.60.

Read Our Latest Stock Analysis on Aytu BioPharma

Latest Aytu BioPharma News

Here’s some of the latest news about AYTU:

  • Neutral Sentiment: Shareholder law firms announced investigations into whether the $2.70 offer fairly values Aytu and whether the board protected investors’ interests. These notices do not establish wrongdoing, but raise questions about the transaction. Ademi LLP shareholder alert
  • Negative Sentiment: Maxim Group and Lake Street Capital both downgraded AYTU from “buy” to “hold.” Lake Street’s $2.70 target is close to the proposed offer price, suggesting limited potential upside if the deal proceeds at the announced terms. Lake Street Capital recommendations
  • Negative Sentiment: The company remained loss-making: its $0.20-per-share quarterly loss was wider than the $0.08 loss a year earlier, and Zacks reported it missed that service’s $0.10-loss consensus. Aytu BioPharma reports Q1 loss

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AYTU. BlackRock Inc. bought a new position in shares of Aytu BioPharma in the second quarter valued at $49,000. Persistent Asset Partners Ltd acquired a new position in shares of Aytu BioPharma during the second quarter valued at about $82,000. Dimensional Fund Advisors LP grew its holdings in shares of Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after buying an additional 8,222 shares during the last quarter. Arete Wealth Advisors LLC acquired a new position in shares of Aytu BioPharma during the first quarter valued at about $135,000. Finally, Crown Advisors Management Inc. acquired a new position in shares of Aytu BioPharma during the second quarter valued at about $430,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Trading Up 46.2%

The company has a quick ratio of 1.00, a current ratio of 1.13 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $2.01 and its 200 day moving average price is $2.27. The company has a market capitalization of $28.91 million, a P/E ratio of -1.49 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. Aytu BioPharma had a negative net margin of 34.34% and a negative return on equity of 74.74%. The company had revenue of $14.84 million for the quarter, compared to analyst estimates of $13.27 million. As a group, equities research analysts predict that Aytu BioPharma Inc. will post -0.16 earnings per share for the current year.

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Featured Stories

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.